Caffeine Enzyme Immunoassay in Neonatal and Pediatric Drug Monitoring
- 1 March 1987
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 9 (1) , 97-103
- https://doi.org/10.1097/00007691-198703000-00017
Abstract
An enzyme immunoassay technique (EMIT) for microdetermina-tions of caffeine was compared with high performance liquid chromatography (HPLC) and evaluated in 113 neonates and young infants, and in 18 asthmatic and 15 epileptic children. The EMIT assay was found reliable in therapeutic drug monitoring. It offers advantages over HPLC in its rapidity and simplicity. It is not affected by hemolysis, hyperbilirubinemia, or lipemia. In the neonate, greater accuracy is obtained with blood samples containing no heparin.This publication has 7 references indexed in Scilit:
- Effect of caffeine on control of breathing in infantile apneaThe Journal of Pediatrics, 1983
- The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infantsThe Journal of Pediatrics, 1981
- Theophylline metabolism in premature infantsClinical Pharmacology & Therapeutics, 1981
- Maturation of caffeine elimination in infancy.Archives of Disease in Childhood, 1979
- Metabolism of theophylline to caffeine in premature newborn infantsThe Journal of Pediatrics, 1979
- Caffeine metabolism in the newbornClinical Pharmacology & Therapeutics, 1979
- Pharmacokinetic profile of caffeine in the premature newborn infant with apneaThe Journal of Pediatrics, 1979